Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Reshape Lifesciences Inc (RSLS)

Reshape Lifesciences Inc (RSLS)
0.4013 -0.0487 (-10.82%) 11:36 ET [NASDAQ]
0.4006 x 7 0.4021 x 1
Realtime by (Cboe BZX)
0.4006 x 7 0.4021 x 1
Realtime 0.3831 -0.0669 (-) 09:29 ET
Quote Overview for Thu, Apr 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3700
Day High
0.4300
Open 0.4000
Previous Close 0.4500 0.4500
Volume 5,111,867 5,111,867
Avg Vol 17,192,994 17,192,994
Stochastic %K 17.15% 17.15%
Weighted Alpha -92.71 -92.71
5-Day Change -0.0554 (-12.58%) -0.0554 (-12.58%)
52-Week Range 0.3445 - 29.0000 0.3445 - 29.0000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,487
  • Shares Outstanding, K 3,305
  • Annual Sales, $ 8,680 K
  • Annual Income, $ -11,390 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.59
  • Price/Sales 0.02
  • Price/Cash Flow N/A
  • Price/Book 0.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -11.83
  • Most Recent Earnings $-3.11 on 11/14/24
  • Next Earnings Date 05/21/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1,182.51
  • Growth Rate Est. (year over year) +184.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3445 +11.79%
on 03/31/25
Period Open: 1.0900
3.0500 -87.37%
on 04/01/25
-0.7049 (-64.67%)
since 03/03/25
3-Month
0.3445 +11.79%
on 03/31/25
Period Open: 4.7000
5.1900 -92.58%
on 01/13/25
-4.3149 (-91.81%)
since 01/03/25
52-Week
0.3445 +11.79%
on 03/31/25
Period Open: 10.1500
29.0000 -98.67%
on 05/29/24
-9.7649 (-96.21%)
since 04/03/24

Most Recent Stories

More News
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS : 0.4000 (-11.11%)
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...

CVS : 68.70 (+0.93%)
EXAS : 44.03 (-1.19%)
ABBV : 203.97 (-0.59%)
RSLS : 0.4000 (-11.11%)
ALLR : 0.8598 (-2.69%)
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS : 0.4000 (-11.11%)
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS : 0.4000 (-11.11%)
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

RSLS : 0.4000 (-11.11%)
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS : 0.4000 (-11.11%)
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

RSLS : 0.4000 (-11.11%)
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS : 0.4000 (-11.11%)
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS : 0.4000 (-11.11%)
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary...

RSLS : 0.4000 (-11.11%)

Business Summary

ReShape Lifesciences Inc. provides weight-loss solutions. It offers an integrated portfolio of proven products and services which manage and treat obesity and metabolic disease. ReShape Lifesciences Inc., formerly known as Obalon Therapeutics, is based in SAN CLEMENTE, CA.

See More

Key Turning Points

3rd Resistance Point 0.8987
2nd Resistance Point 0.8003
1st Resistance Point 0.6251
Last Price 0.4000
1st Support Level 0.3515
2nd Support Level 0.2531
3rd Support Level 0.0779

See More

52-Week High 29.0000
Fibonacci 61.8% 18.0536
Fibonacci 50% 14.6722
Fibonacci 38.2% 11.2909
Last Price 0.4000
52-Week Low 0.3445

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades